ArriVent BioPharma, Inc (AVBP) insider trading
Every open-market stock purchase and sale by ArriVent BioPharma, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $13M over the last 12 months (1 sale). No open-market buys.
- Last insider buy: Hillhouse Investment Management Ltd. (10% owner), $10M, 2 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $13M (1 sale). Last close $30.35 on Jun 4, 2026.
Recent AVBP insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 18, 2026 | Kristine Peterson (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Chris Nolet (Director) | Bought (not open market) | — |
| Jun 18, 2026 | John Hohneker (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Merdad Parsey (Director) | Bought (not open market) | — |
| Feb 2, 2026 | Stuart Lutzker (President) | Bought (not open market) | — |
| Feb 2, 2026 | Zhengbin Yao (CEO) | Bought (not open market) | — |
| Feb 2, 2026 | Robin LaChapelle (COO) | Bought (not open market) | — |
| Feb 2, 2026 | Winston Kung (CFO) | Bought (not open market) | — |
| Feb 2, 2026 | James Paul Kastenmayer (General Counsel) | Bought (not open market) | — |
| Dec 10, 2025 | Hillhouse Investment Management Ltd. (10% owner) | Sold | $13M |
Who's trading AVBP
- Kristine Peterson, Director: other filings, last Jun 18, 2026
- Merdad Parsey, Director: other filings, last Jun 18, 2026
- John Hohneker, Director: other filings, last Jun 18, 2026
- Chris Nolet, Director: other filings, last Jun 18, 2026
- Stuart Lutzker, President: other filings, last Feb 2, 2026
- Zhengbin Yao, CEO: other filings, last Feb 2, 2026
- James Paul Kastenmayer, General Counsel: other filings, last Feb 2, 2026
- Winston Kung, CFO: other filings, last Feb 2, 2026
- Robin LaChapelle, COO: other filings, last Feb 2, 2026
- Hillhouse Investment Management Ltd., 10% owner: sold $13M (1 sale), last Dec 10, 2025
Get free alerts when an insider at ArriVent BioPharma, Inc files a new trade →